Ricevi le ultime notizie sulle azioni BioAtla con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di BCAB

Ultime notizie per

BioAtla

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

BioAtla Inc

Press Releases

General

BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

News

BioAtla to Participate in the Citizens Life Sciences Conference

Earnings

BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress

Health Care

BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting

BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025

BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA

BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025

BCAB

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Celularity

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

CEL-SCI

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Equillium

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

ImmuCell

MiNK Therapeutics

INmune Bio

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

MAIA Biotechnology

Medicus Pharma

MediciNova

OS Therapies

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Serina Therapeutics

Skye Bioscience

vTv Therapeutics Inc. - Class A Common Stock

Comments

BioAtla Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO